Erin Anderson

Erin Anderson is a Senior Associate at Novo Holdings, having joined the firm in January 2020 as part of the Principal Investments team. Her role primarily involves deal sourcing and execution, as well as managing the existing investment portfolio.12

Educational Background

Erin holds a PhD and MS in Bioengineering from Harvard University, where her research was conducted at the School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering. She also earned a BS in Bioengineering from the University of Washington.12

Professional Experience

Before her tenure at Novo Holdings, Erin worked in Corporate Strategy at Novozymes, focusing on strategic initiatives within the life sciences sector. She also has experience in management consulting with the Boston Consulting Group in Copenhagen, where she specialized in commercial due diligence for life science investors and strategic projects for companies in diagnostics, MedTech, and pharmaceuticals. Additionally, she has over ten years of scientific research experience related to drug delivery and tissue engineering, particularly concerning cardiovascular diseases and cancer immunotherapies.12

Erin's combination of scientific expertise and strategic investment experience positions her as a valuable asset within Novo Holdings' investment strategy in the life sciences sector.